🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the effort against increasingly resistant strains of the infection, according to researchers.

A Worldwide Public Health Issue

The sexually transmitted infection are escalating around the world, with data suggesting more than 82 million new cases each year. Particularly high rates are seen in the African continent and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the face of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options at this time.”

Public health authorities are deeply concerned about the increase in drug-resistant strains. The WHO has classified it as a "high-priority threat". Ongoing monitoring found that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Secure Approval

Zoliflodacin, also known as a brand name, was cleared by the US FDA in mid-December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists hope that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in close succession. This medication, which is employed against UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to develop it.

“This approval represents a huge turning point in the therapy of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Testing Outcomes and Worldwide Availability

According to data published in a prominent scientific publication, the new drug successfully treated more than 90% of uncomplicated infections. This places it at an equal footing with the current standard treatment, which involves a dual-drug approach. The study enrolled nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the ability to make available and distribute the drug in numerous regions with limited resources.

Clinicians directly involved have expressed positive views. The availability of a easy-to-administer therapy such as this is described as a "critical tool" for gonorrhoea control. This is considered crucial to lessen the impact of the infection for people and to prevent the spread of untreatable gonorrhoea globally.